Christopher Malsch, DO
Family Medicine · Norristown, PANPI 1851356372
Payments from drug & device makers
Across 334 payments — averaging $45.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Almatica Pharma LLC$7K
- Biohaven Pharmaceuticals, Inc.$1K
- AstraZeneca$891
- Pfizer$748
- Novo Nordisk$731
- AbbVie$551
- plus $4K from 22 others
What the payments were for
- Consulting fees$1,2008%
- Speaking & faculty fees$7,14047%
- Travel & lodging$1741%
- Food & beverage$6,54943%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Almatica Pharma LLC | 21 | $7,220 |
| Biohaven Pharmaceuticals, Inc. | 2 | $1,374 |
| AstraZeneca | 19 | $891 |
| Pfizer | 42 | $748 |
| Novo Nordisk | 28 | $731 |
| AbbVie(2 entities) | 31 | $551 |
| Kowa Pharmaceuticals America, Inc. | 37 | $471 |
| Lilly USA, LLC | 18 | $433 |
| Amarin Pharma, Inc. | 23 | $414 |
| Gilead | 8 | $385 |
| Merck | 21 | $231 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $231 |
| Boehringer Ingelheim | 6 | $215 |
| Axsome Therapeutics, Inc. | 11 | $210 |
| GSK | 4 | $186 |
| Jazz Pharmaceuticals Inc. | 5 | $164 |
| Idorsia Pharmaceuticals US Inc | 8 | $125 |
| Teva Pharmaceuticals USA, Inc. | 5 | $112 |
| Bayer | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $82 |
| Amgen | 2 | $53 |
| Biodelivery Sciences International, Inc. | 3 | $48 |
| Johnson & Johnson | 2 | $34 |
| Novartis | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Intuity Medical Inc | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,084 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $61,076 |
| FarxigaDapagliflozin Propanediol | 44 | $43,407 |
| EliquisApixaban | 58 | $33,733 |
| RybelsusSemaglutide | 16 | $30,272 |
| MounjaroTirzepatide | 28 | $28,535 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $23,902 |
| JardianceEmpagliflozin | 14 | $22,272 |
| TrintellixVortioxetine Hydrobromide | 21 | $17,495 |
| OxycontinOxycodone Hcl | 20 | $15,928 |
| JanuviaSitagliptin Phosphate | 13 | $15,711 |
| VraylarCariprazine Hcl | 11 | $15,659 |
| VascepaIcosapent Ethyl | 28 | $13,812 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,533 |
| KerendiaFinerenone | 12 | $10,798 |
| Rosuvastatin Calcium | 270 | $4,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $731 | $91,34852 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $891 | $54,94057 claims |
| PfizerEliquis | $748 | $33,73358 claims |
| Lilly USA, LLCMounjaro | $433 | $28,53528 claims |
| GSKTrelegy Ellipta | $186 | $23,90226 claims |
| Boehringer IngelheimJardiance | $215 | $22,27214 claims |
| AbbVieVraylar, Synthroid | $551 | $19,83761 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $82 | $17,49521 claims |
| MerckJanuvia | $231 | $15,71113 claims |
| BayerKerendia | $87 | $10,79812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Norristown
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.